Gain Therapeutics reports Q3 net loss of $0.17/share; plans Phase 1b start for GT-02287 by year-end

Gain Therapeutics, Inc.

2024-Q3 EPS reported -$0.78

Net loss per share improved to $0.17 from $0.37 in Q3 2023; R&D spend rose to $2.6M.
Cash and marketable securities $12M as of Sept 30, 2024, down from $16.8M at Dec 31, 2023.
Phase 1 MAD results showed 53% increase in GCase activity; safety and tolerability confirmed.
Initiation of Phase 1b trial in Parkinson's patients expected by end of Q4 2024.
Pre-IND meeting with FDA planned before end of 2024 to support Phase 2 expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.